Skip to content

Product registration clinical trial of WY-2201 Red Blood Cell Life Span Breath Analyzer

A prospective, single-center, paired design clinical trial to evaluate the clinical performance of Red Blood Cell Life Span Breath Analyzer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083228
Enrollment
Unknown
Registered
2024-04-18
Start date
2024-04-22
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemolytic anemia

Interventions

Gold Standard:The RBCS-01A Erythrocyte Life Span Tester (Guangdong medical device registration certificate number 20162220292) produced by Shenzhen Seekya Bio-Sci & Tech Co., Ltd. was used to detect t
Index test:WY-2201 Red Blood Cell Life Span Breath Analyzer

Sponsors

923rd Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 7-75 years old, male or female; (2) Those who intend to undergo red blood cell life measurement, including but not limited to people who have a physical examination and need to be diagnosed differentially, and the source is outpatient or inpatient; (3) Subjects and/or guardians voluntarily participate and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiopulmonary insufficiency; (2) Received blood transfusion within 1 week prior to the test of this clinical trial; (3) Suffering from respiratory infectious diseases, such as influenza, tuberculosis, etc.; (4) Long-term smoking (smoking index = 400) or long-term exposure to second-hand smoke (daily exposure to second-hand smoke for = 1 hour, and exposure to second-hand smoke for = 10 years); (5) Pregnant or lactating women, and those who cannot rule out the possibility of pregnancy; (6) Those who have participated in other drugs, medical devices and other related clinical trials within the past 3 months before the clinical trial; (7) Those who are considered by the investigator to be unsuitable to participate in this clinical trial, including but not limited to: mental illness and cognitive dysfunction, inability to understand the informed consent form, poor compliance, etc.

Design outcomes

Primary

MeasureTime frame
red blood cell life span determination;Detection concordance;

Secondary

MeasureTime frame
Detection accuracy;Device performance evaluation;Usability evaluation;

Countries

China

Contacts

Public ContactXiaolin Yin

Department of Hematology, 923rd Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army.

280662268@qq.com+86 133 2171 7899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026